At Novartis we’re focused on creating innovations that address the most significant unmet needs of patients and societies. In the UK, we have developed a series of unique patient focused resources designed to help people manage different aspects of their condition.
Our resources, often developed in collaboration with experts, range from mobile phone applications to informative video content. We aim to support people affected by conditions such as rare and inflammatory diseases to manage symptoms, better understand their disease and improve doctor/patient communication.
Here we provide further information about the patient resources we have developed, and where you can find out more.
SymTrac™ MS is a free app and educational website designed to support people affected by Relapsing Remitting Multiple Sclerosis (RRMS).
The app enables patients to track their general wellbeing and symptoms over time. Data can be shared with MS specialist teams to help paint a picture of the impact of their disease.
SymTracTM Psoriasis is a free app that has been designed to support patients affected by Psoraisis.
The app enables patients to better understand the pattern and impact of their psoriasis symptoms on their quality of life over time which can help support smarter decisions about their care.
Data recorded on the Symptom Tracker and Dermatology Life Quality Index (DLQI) Questionnaire can be viewed on easy to read graphs. This data along with photos and notes can be exported into a PDF and sent directly to the patients doctor or to themselves to print and take to an appointment.
Chronic myeloid leukaemia (CML) is a type of cancer that affects the blood and bone marrow. In CML the bone marrow produces too many white cells, called granulocytes.
If you have been diagnosed with CML then this educational video may be useful to explain what this means, what treatments are available and how to discuss what comes next with your healthcare professional.
This was made by Novartis Pharmaceuticals UK Ltd. in association with CML Support UK ® and CML-UK.